产生和测量有效疫苗引发HIV特异性CD8+T细胞反应。

Current opinion in HIV and AIDS Pub Date : 2023-11-01 Epub Date: 2023-09-20 DOI:10.1097/COH.0000000000000824
Gina M Borgo, Rachel L Rutishauser
{"title":"产生和测量有效疫苗引发HIV特异性CD8+T细胞反应。","authors":"Gina M Borgo,&nbsp;Rachel L Rutishauser","doi":"10.1097/COH.0000000000000824","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>There is growing consensus that eliciting CD8 + T cells in addition to antibodies may be required for an effective HIV vaccine for both prevention and cure. Here, we review key qualities of vaccine-elicited CD8 + T cells as well as major CD8 + T cell-based delivery platforms used in recent HIV vaccine clinical trials.</p><p><strong>Recent findings: </strong>Much progress has been made in improving HIV immunogen design and delivery platforms to optimize CD8 + T cell responses. With regards to viral vectors, recent trials have tested newer chimp and human adenovirus vectors as well as a CMV vector. DNA vaccine immunogenicity has been increased by delivering the vaccines by electroporation and together with adjuvants as well as administering them as part of a heterologous regimen. In preclinical models, self-amplifying RNA vaccines can generate durable tissue-based CD8 + T cells. While it may be beneficial for HIV vaccines to recapitulate the functional and phenotypic features of HIV-specific CD8 + T cells isolated from elite controllers, most of these features are not routinely measured in HIV vaccine clinical trials.</p><p><strong>Summary: </strong>Identifying a vaccine capable of generating durable T cell responses that target mutationally vulnerable epitopes and that can rapidly intercept infecting or rebounding virus remains a challenge for HIV. Comprehensive assessment of HIV vaccine-elicited CD8 + T cells, as well as comparisons between different vaccine platforms, will be critical to advance our understanding of how to design better CD8 + T cell-based vaccines for HIV.</p>","PeriodicalId":93966,"journal":{"name":"Current opinion in HIV and AIDS","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552829/pdf/","citationCount":"1","resultStr":"{\"title\":\"Generating and measuring effective vaccine-elicited HIV-specific CD8 + T cell responses.\",\"authors\":\"Gina M Borgo,&nbsp;Rachel L Rutishauser\",\"doi\":\"10.1097/COH.0000000000000824\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>There is growing consensus that eliciting CD8 + T cells in addition to antibodies may be required for an effective HIV vaccine for both prevention and cure. Here, we review key qualities of vaccine-elicited CD8 + T cells as well as major CD8 + T cell-based delivery platforms used in recent HIV vaccine clinical trials.</p><p><strong>Recent findings: </strong>Much progress has been made in improving HIV immunogen design and delivery platforms to optimize CD8 + T cell responses. With regards to viral vectors, recent trials have tested newer chimp and human adenovirus vectors as well as a CMV vector. DNA vaccine immunogenicity has been increased by delivering the vaccines by electroporation and together with adjuvants as well as administering them as part of a heterologous regimen. In preclinical models, self-amplifying RNA vaccines can generate durable tissue-based CD8 + T cells. While it may be beneficial for HIV vaccines to recapitulate the functional and phenotypic features of HIV-specific CD8 + T cells isolated from elite controllers, most of these features are not routinely measured in HIV vaccine clinical trials.</p><p><strong>Summary: </strong>Identifying a vaccine capable of generating durable T cell responses that target mutationally vulnerable epitopes and that can rapidly intercept infecting or rebounding virus remains a challenge for HIV. Comprehensive assessment of HIV vaccine-elicited CD8 + T cells, as well as comparisons between different vaccine platforms, will be critical to advance our understanding of how to design better CD8 + T cell-based vaccines for HIV.</p>\",\"PeriodicalId\":93966,\"journal\":{\"name\":\"Current opinion in HIV and AIDS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552829/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current opinion in HIV and AIDS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/COH.0000000000000824\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in HIV and AIDS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/COH.0000000000000824","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

综述目的:人们越来越一致认为,除了抗体外,激发CD8+T细胞可能是预防和治疗有效HIV疫苗所必需的。在这里,我们回顾了疫苗诱导的CD8+T细胞的关键质量,以及最近HIV疫苗临床试验中使用的主要的基于CD8+T的递送平台。最近的发现:在改进HIV免疫原设计和递送平台以优化CD8+T细胞反应方面取得了很大进展。关于病毒载体,最近的试验测试了新的黑猩猩和人类腺病毒载体以及CMV载体。DNA疫苗的免疫原性已经通过电穿孔和与佐剂一起递送疫苗以及作为异源方案的一部分给予它们而增加。在临床前模型中,自扩增RNA疫苗可以产生持久的基于组织的CD8+T细胞。虽然对HIV疫苗来说,重述从精英对照中分离的HIV特异性CD8+T细胞的功能和表型特征可能是有益的,但这些特征中的大多数在HIV疫苗临床试验中没有常规测量。概述:识别一种能够产生持久T细胞反应的疫苗,该疫苗针对易突变的表位,并能够快速拦截感染或反弹的病毒,这对HIV来说仍然是一个挑战。对HIV疫苗引发的CD8+T细胞的全面评估,以及不同疫苗平台之间的比较,对于推进我们对如何设计更好的基于CD8+T的HIV疫苗的理解至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Generating and measuring effective vaccine-elicited HIV-specific CD8 + T cell responses.

Generating and measuring effective vaccine-elicited HIV-specific CD8 + T cell responses.

Generating and measuring effective vaccine-elicited HIV-specific CD8 + T cell responses.

Purpose of review: There is growing consensus that eliciting CD8 + T cells in addition to antibodies may be required for an effective HIV vaccine for both prevention and cure. Here, we review key qualities of vaccine-elicited CD8 + T cells as well as major CD8 + T cell-based delivery platforms used in recent HIV vaccine clinical trials.

Recent findings: Much progress has been made in improving HIV immunogen design and delivery platforms to optimize CD8 + T cell responses. With regards to viral vectors, recent trials have tested newer chimp and human adenovirus vectors as well as a CMV vector. DNA vaccine immunogenicity has been increased by delivering the vaccines by electroporation and together with adjuvants as well as administering them as part of a heterologous regimen. In preclinical models, self-amplifying RNA vaccines can generate durable tissue-based CD8 + T cells. While it may be beneficial for HIV vaccines to recapitulate the functional and phenotypic features of HIV-specific CD8 + T cells isolated from elite controllers, most of these features are not routinely measured in HIV vaccine clinical trials.

Summary: Identifying a vaccine capable of generating durable T cell responses that target mutationally vulnerable epitopes and that can rapidly intercept infecting or rebounding virus remains a challenge for HIV. Comprehensive assessment of HIV vaccine-elicited CD8 + T cells, as well as comparisons between different vaccine platforms, will be critical to advance our understanding of how to design better CD8 + T cell-based vaccines for HIV.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信